Canaccord Genuity Maintains Buy on BioXcel Therapeutics, Maintains $7 Price Target

Benzinga · 06/27/2024 13:32
Canaccord Genuity analyst Sumant Kulkarni maintains BioXcel Therapeutics (NASDAQ:BTAI) with a Buy and maintains $7 price target.